Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results
BA Nock, A Kaloudi, E Lymperis, A Giarika… - Journal of Nuclear …, 2017 - Soc Nuclear Med
We recently introduced the potent gastrin-releasing peptide receptor (GRPR) antagonist 68
Ga-SB3 ( 68 Ga-DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-…
Ga-SB3 ( 68 Ga-DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-…
[HTML][HTML] Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 …
…, P Garnuszek, BA Nock, A Kaloudi… - European Journal of …, 2016 - Elsevier
Introduction From a series of radiolabelled cholecystokinin (CCK) and gastrin analogues,
111 In-CP04 ( 111 In-DOTA-(DGlu) 6 -Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH 2 ) was selected for …
111 In-CP04 ( 111 In-DOTA-(DGlu) 6 -Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH 2 ) was selected for …
[HTML][HTML] NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor …
A Kaloudi, E Lymperis, A Giarika, S Dalm, F Orlandi… - Molecules, 2017 - mdpi.com
Background: The GRPR-antagonist-based radioligands [ 67/68 Ga/ 111 In/ 177 Lu]NeoBOMB1
have shown excellent theragnostic profiles in preclinical prostate cancer models, while [ …
have shown excellent theragnostic profiles in preclinical prostate cancer models, while [ …
Radiometal-dependent biological profile of the radiolabeled gastrin-releasing peptide receptor antagonist SB3 in cancer theranostics: Metabolic and biodistribution …
E Lymperis, A Kaloudi, W Sallegger… - Bioconjugate …, 2018 - ACS Publications
Recent advances in oncology involve the use of diagnostic/therapeutic radionuclide-carrier
pairs that target cancer cells, offering exciting opportunities for personalized patient treatment…
pairs that target cancer cells, offering exciting opportunities for personalized patient treatment…
[HTML][HTML] [99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
BA Nock, A Kaloudi, P Kanellopoulos, B Janota… - Cancers, 2021 - mdpi.com
Simple Summary Radiolabeled gastrin-releasing peptide receptor (GRPR)-antagonists have
been proposed for diagnostic imaging and radionuclide therapy—theranostics—of human …
been proposed for diagnostic imaging and radionuclide therapy—theranostics—of human …
Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon
A Kaloudi, BA Nock, E Lymperis… - Cancer Biotherapy …, 2016 - liebertpub.com
Minigastrin radiotracers, such as [ 111 In-DOTA]MG0 ([ 111 In-DOTA-DGlu 1 ]minigastrin),
have been considered for diagnostic imaging and radionuclide therapy of CCK2R-positive …
have been considered for diagnostic imaging and radionuclide therapy of CCK2R-positive …
[HTML][HTML] Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation
A Kaloudi, BA Nock, E Lymperis, R Valkema… - EJNMMI research, 2016 - Springer
Background We have recently shown that treatment of mice with the neutral endopeptidase (NEP)
inhibitor phosphoramidon (PA) improves the bioavailability and tumor uptake of …
inhibitor phosphoramidon (PA) improves the bioavailability and tumor uptake of …
Novel bifunctional DATA chelator for quick access to site-directed PET 68 Ga-radiotracers: preclinical proof-of-principle with [Tyr 3] octreotide
BA Nock, A Kaloudi, J Nagel, JP Sinnes… - Dalton …, 2017 - pubs.rsc.org
Molecular imaging of tumors with the PET radionuclide 68Ga has gained momentum in
clinical oncology due to the expanding availability of commercial 68Ge/68Ga-generators in …
clinical oncology due to the expanding availability of commercial 68Ge/68Ga-generators in …
[111In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors
…, R Cescato, B Waser, A Tatsi, A Kaloudi… - Journal of medicinal …, 2014 - ACS Publications
Radiolabeled pansomatostatin-like analogues are expected to enhance the diagnostic
sensitivity and to expand the clinical indications of currently applied sst 2 -specific radioligands. …
sensitivity and to expand the clinical indications of currently applied sst 2 -specific radioligands. …
[99mTc]Tc-DGA1, a Promising CCK2R-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography
A Kaloudi, P Kanellopoulos, T Radolf… - Molecular …, 2020 - ACS Publications
Radiolabeled gastrin analogues have been proposed for theranostics of cholecystokinin
subtype 2 receptor (CCK 2 R)-positive cancer. Peptide radioligands based on other receptor …
subtype 2 receptor (CCK 2 R)-positive cancer. Peptide radioligands based on other receptor …